Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K RE: LD MICRO - BIOLASE, INC | d449210d8k.htm |
 Fred
Furry, COO & CFO December 6, 2012
Nasdaq: BIOL
PAGE 1
Exhibit 99.1 |
 Safe
Harbor Statement PAGE 2
This presentation may contain forward-looking statements that are based on our
current expectations, estimates and projections about our industry as well as
management’s beliefs and assumptions. Words such as “anticipates,”
“expects,” “intends,” “plans,”
“believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar
expressions are intended to identify forward-looking statements. These statements
include projections about our future earnings and margins and speak only as of
the date hereof. Such statements are based upon the information available to us
now and are subject to change. We will not necessarily inform you of such changes. These statements are not
guarantees of future performance and are subject to certain risks, uncertainties and
assumptions that are difficult to predict. Therefore our actual results could
differ materially and adversely from those expressed in any forward-looking
statements as a result of various factors. The important factors which could cause
actual results to differ materially from those in the forward-looking
statements include, among others, a downturn or leveling off of demand for our
products due to the availability and pricing of competing products and technologies,
adverse international market or political conditions, a domestic economic
recession, the volume and pricing of product sales, our ability to control cost
intellectual property disputes, the effects of natural disasters and other events
beyond our control and other factors including those detailed in BIOLASE’s
filings with the Securities and Exchange Commission including its prior filings on
Form 10-K and 10-Q.
|
 •
We are a biomedical company focused on developing, manufacturing,
and selling dental lasers using our revolutionary, proprietary WaterLase
technology.
•
Also a marketer & distributor of:
–
dental imaging equipment,
–
intra-oral scanners, and
–
other products designed for dental & medical procedures.
•
Net revenue of $48.8M in 2011; up 87% over 2010.
•
Projecting gross revenue of $55M to $58M in 2012.
BIOLASE Company Overview
PAGE 3 |
 Step
Technology
BIOLASE Product Offering
Diagnose and establish
treatment protocol
3D cone beam imaging
•
NewTom
(QR/Cefla)
•
DaVinci
Imaging
(Cefla)
Treatment: all tissue surgical
device
WaterLase
•
WaterLase iPlus
•
WaterLase MDX
•
WaterLase MD Turbo
Treatment: soft tissue
surgical device
Diode laser
•
EPIC
10
diode
laser
•
iLase
portable, battery operated diode
laser
Impression taking for crowns
Digital
•
TRIOS
intra-oral scanner (3Shape)
BIOLASE’s Total Technology Solution
PAGE 4 |
 •
WaterLase is a biological method to cut tissue.
•
Water molecules within tissue absorb the laser energy from
the WaterLase, expand, and vaporize, which causes a
biological ablation of the tissue.
–
There is very little trauma or bleeding,
–
No heat or vibration are generated, and
–
Causes little or no pain.
–
Significantly reduces cross contamination.
WaterLase All-Tissue Lasers
PAGE 5
Extensive patent protection. |
 How It
Works: WaterLase High Speed Cutting PAGE 6 |
 WaterLase Side by Side with Drill
PAGE 7 |
 WaterLase Soft Tissue Lingual Frenectomy
PAGE 8 |
 The
WaterLase aiming beam
does not cut the
tissue or generate
heat. The tissue
is cut biologically,
with little or no
pain, when the
laser energizes
water at the
molecular level.
PAGE 9
WaterLase Atraumatic Pediatric Tooth Extraction |
 •
176,000 dentists in US & Canada.
1
•
1.2M+ dentists in 134 countries.
–
rapid growth in emerging economies
2
e.g. China, India & Indonesia.
•
Current market penetration .
–
approx. 5.0% of dental practices in US.
–
approx. 1.5% worldwide.
•
Each incremental 1% market penetration equals over $600M revenue.
•
Total market opportunity is in excess of $50B.
BIOLASE’s Market Opportunity
Est. total global market
BIOLASE systems sold worldwide 1998-present
1
American Dental Association.
2
World Federation of Dentistry.
PAGE 10
20,000+
1,200,000 |
 Dominant Market Position
Hard-tissue Dental Laser Market
Total Dental Laser Market
80%
45%
BIOLASE Market Share |
 •
EPIC 10 total diode solution
–
regulatory
clearance
late
Q3
(EU)
&
early
Q4
(US)
2012.
–
cleared for 3 unique uses:
Soft Tissue Surgery,
Whitening,
Pain Therapy.
•
iLase
–
portable diode laser.
–
no foot pedal, power cord, or external controls.
Diode Soft-Tissue Dental Lasers |
 In-Licensed Products
PAGE 13
•
NewTom and Cefla
3D cone beam
imaging products
–
medical grade
imaging technology.
–
less cost, less
radiation exposure.
–
U.S. & Canada
distribution
agreement through
Feb 2015.
•
TRIOS intra-oral
scanner and cart
–
digital impression
taking.
–
handheld scanner,
operator's control cart,
and software.
–
North American
distribution agreement
through Aug 2017. |
 •
291 patents issued & pending
•
70% are related to WaterLase technology & medical lasers
Extensive Patent Portfolio
Issued &
Active
Pending
Total
U.S.
81
52
133
International
81
77
158
Total
162
129
291
PAGE 14 |
 Sales
and Marketing PAGE 15
•
Returned to direct sales model in N. America in August 2010
•
Currently consists of 47-person team:
–
37 direct outside sales
–
10 inside sales representatives and lead generators
•
Targeted plans for 42-45 outside reps and 12-15 inside reps
•
Global sales offices
–
Current: Irvine, CA (USA), Floss (Germany), Madrid (Spain),Shanghai
(China), and Mumbai (India)
–
Planned: Dubai (UAE) and Rio de Janero (Brazil) |
 Gross
Revenue and Influencers Launched
Cefla’s NewTom
Cone Beam
Imaging products
Introduced iLase™
hand-held soft-
tissue diode laser
Introduced DaVinci
Imaging™
products
Launched
WaterLase
®
iPlus™
all-tissue laser
Launched 3Shape’s
TRIOS™
intra-oral
scanner
CE Mark & FDA
clearance for EPIC 10
Ended exclusive
distribution
agreement w.
Schein
Introduced
WaterLase
®
MDX™
all-
tissue lasers
PAGE 16
$0.0
$5.0
$10.0
$15.0
$20.0
Q1 '10
Q2 '10
Q3 '10
Q4 '10
Q1 '11
Q2 '11
Q3 '11
Q4 '11
Q1 '12
Q2 '12
Q3 '12
Q4 '12
$4.4
$5.9
$6.2
$9.7
$10.6
$12.1
$13.1
$13.2
$12.3
13.3
$13.8
$16.5
17.5
$
- |
 •
Continued adoption of core WaterLase products.
•
Drive sales of EPIC 10 diode soft-tissue laser.
•
Growth of Imaging Division (cone beam and cad-cam)
•
Additional new product introductions based on our core technologies.
–
Two
510(k) submissions currently under FDA review.
–
Three additional submissions planned to be filed in near term.
•
Expand into new markets beyond dentistry.
Growth Strategy
PAGE 17 |
 •
Ongoing growth in WaterLase sales.
•
Recent & planned new product introductions.
–
EPIC 10 & TRIOS introduced second half of 2012.
–
Additional product launches based on core technologies planned.
•
Strong IP protection with additional patents pending.
•
Addressing $50 dental laser market opportunity.
–
Significant opportunities in other medical markets.
•
Improved financial position.
Investment Considerations
PAGE 18 |
 BIOLASE Corporate Headquarters in Irvine, California
•
Over 180 employees worldwide
•
Sales offices in Floss (Germany), Madrid (Spain),
Shanghai (China), and Mumbai (India); expansion
planned in Dubai (UAE), and Rio de Janero (Brazil)
•
Floss also has service and manufacturing capabilities
BIOLASE Europe in Floss, Germany
•
Corporate HQ: Irvine, California
•
57,000 sq. ft. facility houses finance &
administrative, sales, marketing, customer care,
training, manufacturing, and R&D
•
Can accommodate growth to $250 million
BIOLASE Today
PAGE 19 |
 Fred
Furry COO & CFO, BIOLASE, Inc.
949.226.8124
ffurry@biolase.net
Lisa Wilson
President, In-Site Communications, Inc.
212.759.3929
lwilson@insitecony.com
PAGE 20 |